Cardiolife registered for Commercial Use in Brazil

Cardiolife is pleased to announce that its AI-powered cardiac diagnostic software is now registered for commercial use in Brazil by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory authority. This milestone marks Cardiolife’s entry into Latin America’s most important healthcare market and paves the way for broad deployment of its technology.

Brazil represents a high-growth opportunity for healthcare innovation, particularly in cardiovascular diagnostics, and Cardiolife is now positioned to serve this market with full commercial capability.

“This registration is a pivotal step for Cardiolife,” said Kristin Lied, CEO of Cardiolife. “Brazil is a key market for us — dynamic, fast-growing, and deeply committed to innovation in healthcare. Entering Brazil reflects our dedication to bringing faster, more consistent ECG diagnosis and prevention to more people worldwide. We look forward to partnering with healthcare institutions across the country to make that vision a reality.”

Cardiolife’s AI-driven ECG diagnostics assist clinicians in interpreting ECGs with precision and consistency, supporting earlier detection of heart disease and improved patient outcomes. With the ANVISA registration now completed, the company will focus on market rollout, distribution partnerships, and continued clinical validation in Brazil.

The company remains committed to global growth while maintaining its focus on clinical excellence and regulatory compliance.